New biologic STR-P004 tested for tough autoimmune cases
NCT ID NCT07143617
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests the safety of a new biologic drug called STR-P004 in 39 adults with autoimmune diseases that have not responded to standard treatments. Participants receive the drug by IV infusion, and researchers monitor for side effects and how the drug behaves in the body. The goal is to see if it is safe enough to study further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
STR-P004 (a biologic drug given by IV infusion)
What this could lead to
If safe and effective, this could point toward a new treatment option for people with hard-to-control autoimmune diseases.
What could go wrong
This is a very early, small safety study with only 39 participants. It is not designed to prove the drug works, and side effects or lack of benefit are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••